Daratumumab Improves Progression-Free Survival for Patients with Multiple Myeloma
A summary of clinical trial results showing that daratumumab plus lenalidomide and dexamethasone improved progression-free survival for patients with relapsed or refractory disease.
Media Type: Html
- SourceUrl: https://www.cancer.gov/publishedcontent/syndication/1070678.htm
- Syndication ID: 19294
- Language: English
- Source: National Cancer Institute (NCI)
- Date Syndication Captured: Monday, March 23, 2020 at 07:12 PM
- Date Syndication Updated: Monday, August 03, 2020 at 06:25 AM
Embed Code Snippet
To get the embed code snippet please Login.
